NCT04532268View on ClinicalTrials.gov

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 23, 2020

Primary Completion Date

August 23, 2023

Study Completion Date

August 23, 2026

Conditions
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma,B Cell
Interventions
DRUG

Humanized CD19 CAR-T cells

Each subject receive humanized CD19 CAR T-cells by intravenous infusion

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER

NCT04532268 - A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL | Biotech Hunter | Biotech Hunter